March 2022
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This conference examined what is needed to improve diagnostic speed and outcomes.
It took place with the MHRA considering responses to its consultation on the future regulation of medical devices.
The discussion was an opportunity for delegates to assess the future outlook, including:
- the future regulatory approach - the potential for increased transparency and flexibility whilst maintaining patient safety, and alignment with international practices
- keeping pace with developments - including taking forward in vitro diagnostics utilised during the pandemic, and options for regulating innovative software
- patients and care - latest thinking on improving access to innovation
- sustainability - ways to lead on new practices that support reducing carbon footprint, including the re-use of devices
Further sessions looked at supporting continued research and innovation, investment and modernising diagnostics, including funding announced for NHS technology to modernise and improve diagnostics efficiency as part of wider efforts to address waiting lists - as well as the Medicines and diagnostic manufacturing transformation fund to support the supply chain and skills.
Additional areas for discussion included:
- industry partnerships
- staff recruitment and retention
- learning from the response to COVID-19
- opportunities for efficiencies
We are very pleased to have been able to include keynote sessions with Dr Sarah Byron, Programme Director, Centre for Health Technology Evaluation, NICE; Professor Michael Messenger, Principal Scientific Advisor for In Vitro Diagnostics, MHRA; and. Professor Sir Mark Caulfield, Vice Principal (Health), Queen Mary University of London; Chief Executive Officer, Barts Life Sciences; and former Chief Scientist, Genomics England.
There were also keynote contributions from: Professor Louise Jones, Chair, Genomics and Reproductive Science Specialty Advisory Committee, Royal College of Pathologists; and Professor of Breast Pathology, Barts Cancer Institute; Stephen Lee, Director, Diagnostics Regulation, Association of British Healthcare Industries; and Doris-Ann Williams, Chief Executive, British In Vitro Diagnostics Association.
The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the DHSC; the MHRA; the OLS; the UKHSA; BEIS; the IPO; the Department of Health, NI; DIT; the Government Office for Science; GLD; The Scottish Government; and the Welsh Government - as well as parliamentary pass-holders from both Houses of Parliament.
